|
| Peptide | Description | Evaluated condition | Clinical trial phase | Company | Proposed mechanism of action |
|
| AA139 | Originates from arenicin-3 | Urinary tract infection | Phase I | Adenium Biotech | Interruption of phospholipid transportation pathways, membrane dysregulation |
| AB103 | A peptide mimetic of CD28 | Necrotizing soft tissue infections | Phase III | Atox Bio | Attenuate cd28 signaling during bacterial infection |
| Dalbavancin | Semisynthetic lipoglycopeptide | Gram-positive osteoarticular infections | Phase IV | Infectious Diseases Physicians, Inc. | Inhibit transglycosylation and transpeptidation for cell-wall synthesis |
| Pexiganan | Analogue of magainin-2 | Infected diabetic ulcers | Phase III (failed) | Dipexium Pharmaceuticals, Inc. | Cell membrane disruption |
| LL37 | A 37 amino acid cationic peptide of the hCAP18 protein | Venous leg ulcers and diabetic foot ulcers | Phase IIa | Promore Pharma | Modulate the inflammatory phase |
| SAAP-148 | An LL-37-derived peptide | Atopic dermatitis and methicillin-resistant staphylococcus aureus infections | Preclinical | Madam Therapeutics | Cell membrane modulators |
| Oritavancin | A semisynthetic lipoglycopeptide | Acute bacterial skin and skin structure infections | Phase III | Melinta Therapeutics, Inc. | Inhibit cell wall biosynthesis |
| PAC-113 | A 12-amino acid peptide derived from the histatin | Candidiasis infection | Phase IIb | Pacgen Biopharmaceuticals Corporation | Cell membrane permeability enhancers; reactive oxygen species stimulants |
| SGX942 | Synthetic 5-amino acid peptide | Oral mucositis | Phase III | Soligenix | Target the intracellular control pathways |
| Murepavadin (POL7080) | A 14-amino-acid cyclic peptide based on protegrin-1 | Pseudomonas infections | Preclinical | Polyphor Ltd. | Target the Gram-negative bacterial outer membrane proteins |
| Novexatin (NP213) | A cyclic arginine-based heptamer | Toenail infections | Phase I/IIa | NovaBiotics Ltd. | Disrupting bacterial cell membranes |
| hLF1-11 | The first eleven amino acids of the natural human lactoferrin | Infection of bone marrow stem cell transplantations | Phase II | Am-Pharma | Modulation of the immune system |
| Brilacidin | A mimic of defensin | Acute bacterial skin and skin structure infection | Phase III | Innovation Pharmaceuticals Inc. | Disrupting bacterial cell membranes |
| PXL01 | A synthetic peptide derived from the human lactoferricin peptide | Postsurgical adhesions and scars | Phase III | Promore Pharma | Immunomodulation and enhancement of fibrinolytic activity |
| OG716 | A derivative of mutacin 1140 | Clostridium difficile infection in enteritis | Preclinical | Oragenics, Inc. | Transmembrane lipid II-mediated pore formation |
| Omiganan | A synthetic 12 amino acid peptide, analogue of indolicidin | Catheter infections | Phase II | Cutanea life sciences | Cell membrane permeability enhancers |
|
